AVS Pulse — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AVS Pulse is a private, clinical-stage medical device company pioneering a next-generation intravascular lithotripsy (IVL) system called Pulse IVL™. Its core innovation is a unique mechanism of action that generates rapid pulsatile energy waves to fracture calcified plaques, which is positioned as an improvement over existing IVL technologies in terms of deliverability and ease of use. The company is currently executing a U.S. pivotal IDE study for peripheral artery disease (PAD) and planning expansion into coronary and carotid indications. Backed by a $36M Series B financing, AVS is preparing for a potential U.S. commercial launch in the competitive calcified lesion treatment market.

CardiovascularPeripheral Artery DiseaseCoronary Artery DiseaseCarotid Artery Disease

Technology Platform

Pulse Intravascular Lithotripsy (IVL) system that uses high-frequency (15/second) pulsatile pressure waves generated from pressurized CO2 to fracture arterial calcium multi-directionally along a balloon catheter.

Opportunities

The large and growing market for treating severely calcified arteries, which is underserved by existing technologies, presents a major opportunity.

AVS's differentiated, high-speed pulsatile mechanism could capture market share by offering improved deliverability and procedural efficiency, especially in complex coronary and carotid cases.

Risk Factors

Key risks include failure to achieve positive results in the ongoing pivotal trial, intense competition from established market leaders like Shockwave Medical (Philips), and the challenge of building a commercial organization and gaining physician adoption post-approval in a crowded market.

Competitive Landscape

AVS competes directly in the intravascular lithotripsy (IVL) market, which is currently dominated by Shockwave Medical (acquired by Philips). Other competitors include companies with orbital atherectomy, rotational atherectomy, and laser atherectomy systems. AVS's strategy is to differentiate on a faster, more deliverable, and user-friendly IVL mechanism.

More companies in Digital Health & Biotech SaaS →More companies in United States →